Immuneering Corporation
Immuneering Corporation (IMRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
IMRX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsImmuneering Corporation trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | -$0.00B | -100.00% |
| 2022-12-31 | $0.00B | -$0.00B | -84.76% |
| 2021-12-31 | $0.00B | -$0.00B | -10.02% |
| 2020-12-31 | $0.00B | +$0.00B | +20.41% |
| 2019-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Immuneering Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Immuneering Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Immuneering Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IMRX revenue · 4 questionsIMRX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Immuneering Corporation SEC filings · GAAP · Immuneering Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026